These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18487582)

  • 1. Is single-agent chemotherapy acceptable in platinum-sensitive relapsed ovarian cancer?
    Abou-Jawde RM; Oberoi SS
    J Clin Oncol; 2008 May; 26(15):2602-3; author reply 2603. PubMed ID: 18487582
    [No Abstract]   [Full Text] [Related]  

  • 2. [Related-factor analysis on efficacy of re-platinum chemotherapy in platinum-sensitive recurrent ovarian carcinoma].
    Cheng XD; Lü WG; Xie X; Huang XF; Ye DF; He HC; Ding ZM
    Zhonghua Fu Chan Ke Za Zhi; 2003 Nov; 38(11):670-2. PubMed ID: 14728853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).
    Meier W; du Bois A; Reuss A; Kuhn W; Olbricht S; Gropp M; Richter B; Lück HJ; Kimmig R; Pfisterer J
    Gynecol Oncol; 2009 Aug; 114(2):199-205. PubMed ID: 19446314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer.
    Pérez-López ME; Curiel T; Gómez JG; Jorge M
    Anticancer Drugs; 2007 Jun; 18(5):611-7. PubMed ID: 17414631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival and determinants of response to third-line chemotherapy in sensitive recurrent ovarian cancer patients.
    Villa A; Parazzini F; Scarfone G; Guarnerio P; Bolis G
    Br J Cancer; 1999 Jan; 79(2):373-4. PubMed ID: 9888485
    [No Abstract]   [Full Text] [Related]  

  • 6. Carboplatin.
    Med Lett Drugs Ther; 1989 Sep; 31(800):83-4. PubMed ID: 2671623
    [No Abstract]   [Full Text] [Related]  

  • 7. Second-line chemotherapy of epithelial ovarian cancer.
    Markmon M
    Expert Rev Anticancer Ther; 2003 Feb; 3(1):31-6. PubMed ID: 12597347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxaliplatin for the treatment of ovarian cancer.
    Bogliolo S; Cassani C; Gardella B; Musacchi V; Babilonti L; Venturini PL; Ferrero S; Spinillo A
    Expert Opin Investig Drugs; 2015; 24(9):1275-86. PubMed ID: 26125301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concerns with "maintenance chemotherapy" for patients with recurrent platinum-sensitive ovarian cancer.
    Markman M
    Gynecol Oncol; 1999 Jun; 73(3):469-70; author reply 470-2. PubMed ID: 10366485
    [No Abstract]   [Full Text] [Related]  

  • 10. Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies.
    Markman M
    Trends Pharmacol Sci; 2008 Oct; 29(10):515-9. PubMed ID: 18760845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary cytoreduction plus oxaliplatin-based HIPEC in platinum-sensitive recurrent ovarian cancer patients: a pilot study.
    Fagotti A; Paris I; Grimolizzi F; Fanfani F; Vizzielli G; Naldini A; Scambia G
    Gynecol Oncol; 2009 Jun; 113(3):335-40. PubMed ID: 19345401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer.
    Vergote I; Amant F
    Gynecol Oncol; 2006 Sep; 102(3):415-7. PubMed ID: 16979430
    [No Abstract]   [Full Text] [Related]  

  • 13. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
    Ozols RF
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does secondary surgical cytoreduction improve survival in women with advanced ovarian cancer?
    Munkarah A
    Nat Clin Pract Oncol; 2005 Apr; 2(4):188-9. PubMed ID: 16264930
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical application of oxaliplatin in epithelial ovarian cancer.
    Fu S; Kavanagh JJ; Hu W; Bast RC
    Int J Gynecol Cancer; 2006; 16(5):1717-32. PubMed ID: 17009963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of recurrent ovarian carcinoma: current status and future directions.
    Martin LP; Schilder RJ
    Semin Oncol; 2009 Apr; 36(2):112-25. PubMed ID: 19332246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re: Dr. Markman's editorial "Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials" Gynecol. Oncol. 106(2); 279-81: 2007.
    Patsner B
    Gynecol Oncol; 2008 Jan; 108(1):254-5; author reply 255. PubMed ID: 17963827
    [No Abstract]   [Full Text] [Related]  

  • 18. Narrow-band imaging in laparoscopic management of recurrent platinum sensitive ovarian cancer.
    Gagliardi ML; Polito S; Fagotti A; Fanfani F; Scambia G
    J Minim Invasive Gynecol; 2013; 20(1):10-2. PubMed ID: 23312240
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Herzog TJ; Powell MA; Rader JS; Gibb RK; Lippmann L; Coleman RL; Mutch DG
    Gynecol Oncol; 2008 Dec; 111(3):467-73. PubMed ID: 18834619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming platinum resistance in ovarian cancer treatment: from clinical practice to emerging chemical therapies.
    Tomao F; Marchetti C; Romito A; Di Pinto A; Di Donato V; Capri O; Palaia I; Monti M; Muzii L; Benedetti Panici P
    Expert Opin Pharmacother; 2017 Oct; 18(14):1443-1455. PubMed ID: 28521614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.